Trial Profile
A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin; Nordilet) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Short stature
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
- 04 Apr 2016 Primary endpoint (Height velocity (Ht-V) after 6 months treatment) has been met, according to results presented at The 98th Annual Meeting of the Endocrine Society.
- 04 Apr 2016 Results assessing efficacy of recombinant human growth hormone (hGH) (Norditropin; Nordilet) presented at The 98th Annual Meeting of the Endocrine Society.
- 18 Feb 2014 New trial record